Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

A sup 125 I-radioimmunoassay for measuring androstenedione in serum and in blood-spot samples from neonates

Journal Article · · Clinical Chemistry (Winston-Salem, North Carolina); (USA)
OSTI ID:5546814
; ;  [1]
  1. Stobhill Hospital, Glasgow (England)
We developed a radioimmunoassay with a gamma-emitting radioligand to measure androstenedione in human serum and in dried blood-spot samples from newborns. Antisera were raised in rabbits against androstenedione linked to bovine serum albumin at positions 3, 6, or 11 on the steroid nucleus. Radioligands were prepared by linking ({sup 125}I)iodohistamine at positions 3, 6, or 11. Linkages were through either carboxymethyloxime or hemisuccinate bridges. All label and antibody combinations were examined, and the most sensitive and specific combination (antiserum raised against androstenedione-3-carboxymethyloxime-bovine serum albumin with an androstenedione-carboxymethyloxime-({sup 125}I)iodohistamine label) was selected for full evaluation. We report the performance of these selected reagents in an immunoassay for androstenedione in both serum and dried blood-spot samples from neonates. We measured concentrations of androstenedione in serum under normal and pathological conditions such as congenital adrenal hyperplasia and polycystic ovarian disease. Diurnal variation in normal men was observed. Androstenedione was measured in blood spots from neonates born at term or prematurely, with respiratory distress syndrome, or with congenital adrenal hyperplasia.
OSTI ID:
5546814
Journal Information:
Clinical Chemistry (Winston-Salem, North Carolina); (USA), Journal Name: Clinical Chemistry (Winston-Salem, North Carolina); (USA) Vol. 35:8; ISSN 0009-9147; ISSN CLCHA
Country of Publication:
United States
Language:
English